Golimumab
Golimumab belongs to a class of biologic medications known as tissue necrosis factor alpha (TNF-α)-blockers. Excess amounts of TNF-α causes the immune system to attack healthy cells in the target area such as gastrointestinal (GI) tract or joints, resulting in inflammation. Golimumab binds to TNF-α, blocking its action to help improve symptoms.
Nufactor carries the following golimumab brands:
Brand (Manufacturer)
FDA-approved indication(s) [abbreviated]
FDA-approved indication(s) [abbreviated]:
- Ankylosing spondylitis (adult)
- Psoriatic arthritis (2+ years old)
- Rheumatoid arthritis (RA) in combination with methotrexate (adult)
- Polyarticular Juvenile Idiopathic Arthritis (pJIA) (2+ years old)
FDA-approved indication(s) [abbreviated]:
- Ankylosing spondylitis (adult)
- Psoriatic arthritis alone or in combination with methotrexate (adult)
- Rheumatoid arthritis (RA), in combination with methotrexate (adult)
- Ulcerative colitis (UC) (adult)
Last reviewed 08/08/24
The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.
